Zeposia, ozanimod
Named-patient access overview. Zeposia is coordinated by Reserve Meds for international patients through cross-border sourcing coordinated with your treating doctor.
Ask about Zeposia
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
About Zeposia
Zeposia (ozanimod) is manufactured by Bristol Myers Squibb and indicated for Relapsing multiple sclerosis and moderate-to-severe ulcerative colitis. It is an oral small molecule (S1P receptor 1/5 modulator) approved by the US FDA in 2020 and may be accessible to international patients through Named Patient Program or personal-import pathways.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
How Reserve Meds coordinates Zeposia
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Zeposia for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Zeposia is sourced from a US-licensed pharmaceutical wholesale partner with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Country coverage
Reserve Meds publishes detailed country deep-dives for our most-requested medications. If you are pursuing Zeposia for a patient in the UAE, Saudi Arabia, India, Egypt, Pakistan, or another market we serve, submit a request and our clinical team will match the destination to the appropriate regulatory pathway and timeline.
Reserved for you. Zeposia is in our coordination scope. Country-specific pricing and timing are confirmed once a coordinator reviews your case.
Start a request for Zeposia
Send us the medicine and your country. We reply within one business day with case-specific feasibility, timeline, and a formal quote.